Arcus Capital Partners’s Pfizer PFE Stock Holding History

Arcus Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-695	Closed	-$35.6K	–	278
2022 Q4	$35.6K	Buy	+695	New	+$33.3K	0.01%	195
2018 Q4	–	Sell	-5,103	Closed	-$213K	–	110
2018 Q3	$213K	Buy	+5,103	New	+$196K	0.1%	100
2018 Q2	–	Sell	-9,697	Closed	-$326K	–	107
2018 Q1	$326K	Sell	9,697 -4,231	-30%	-$145K	0.18%	73
2017 Q4	$479K	Sell	13,928 -591	-4%	-$20.2K	0.27%	62
2017 Q3	$492K	Buy	+14,519	New	+$467K	0.26%	67
2016 Q1	–	Sell	-4,925	Closed	-$151K	–	80
2015 Q4	$151K	Buy	+4,925	New	+$155K	0.11%	67

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arcus Capital Partners's PFE Position: Q1 2023 in Review

Arcus Capital Partners sold out of Pfizer (PFE) in Q1 2023, closing a stake of 695 shares — an estimated $35.6K sold.

Arcus Capital Partners first reported a position in PFE in Q4 2015 and held it in 6 quarters. The position peaked at $492K in Q3 2017. 3,105 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

Arcus Capital Partners reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
Arcus Capital Partners sold 695 Pfizer shares in Q1 2023, an estimated $35.6K.
Arcus Capital Partners first reported a position in Pfizer in Q4 2015 and held it in 6 quarters.
Arcus Capital Partners's Pfizer position peaked at $492K in Q3 2017.
3,105 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.